Background {#Sec1}
==========

Colorectal cancer (CRC) is a leading contributor to cancer mortality worldwide \[[@CR1], [@CR2]\]. Surgical treatment is the mainstay for elimination of CRC and continuity of life \[[@CR3], [@CR4]\]. However, patients with a high risk of postoperative progression of CRC require additional interventions and informed decision-making with the help of physicians \[[@CR3]--[@CR5]\]. Among the vast spectrum of clinicopathological information \[[@CR3], [@CR6]\], the American Joint Committee on Cancer (AJCC) stages of CRC are fundamental for choosing optimal clinical interventions, and their use remains at the forefront of predicting and treating CRC \[[@CR7]\]. Unfortunately, many observations are not consistent with the assumed relationship between advanced anatomical stages and reduced survival probabilities. For instance, disease recurs in 25 % of patients with early CRC who are node-negative following curative resection \[[@CR8]\]. Patients with stage II CRCs with low-risk features more frequently encounter adverse events than those with high-risk features \[[@CR9]\]. Postoperative adjuvant therapies for patients with stage II CRC with fewer than 12 recovered nodes or other risk factors have not gained a clear survival benefit as expected \[[@CR10]--[@CR12]\]; however, a substantial improvement in survival has been achieved for patients with stage III CRC \[[@CR11], [@CR12]\]. Therapeutic effects only partially explain the conspicuous survival inhomogeneity within stage III CRC although stage migrations due to inadequate pathologic assessment may also play a role \[[@CR13], [@CR14]\]. Metastatic CRC after curative hepatic resection has a 5-year overall survival (OS) of 47.7 to 57.6 % \[[@CR15], [@CR16]\], while the OS of most patients with unresectable metastatic CRC is extremely poor \[[@CR17]\]. Survival of CRC remains poor for multiple reasons that are not limited to tumor-related factors. Despite the increased complexity among several modifications of the AJCC cancer staging manuals \[[@CR14]\], the AJCC stages have intrinsic defects as an anatomy-dependent rather than multidiscipline-integrated metric \[[@CR18]\]. Moreover, the AJCC stages force categorization of tumor dissemination in a stepwise fashion, causing additional loss of predictive accuracy \[[@CR18], [@CR19]\]. A consequential issue has thus emerged: both the 5-year cancer-specific survival (CSS) and OS are heterogeneous among patients with the same stage of CRC \[[@CR14]\].

Many useful factors are not sufficiently utilized in clinical prognostication. The plasma carcinoembryonic antigen (CEA) concentration is strongly predictive \[[@CR15], [@CR19]\] and plays roles in staging other than indicating recurrence. Patient-specific factors such as sex, ethnicity, and marital status are also associated with survival \[[@CR1], [@CR2], [@CR20], [@CR21]\], representing untapped information that may be useful for individualized therapies and outcomes. Many other parameters included in routine pathologic reports are also apparent survival determinants, including tumor location, size, histology, grade, differentiation, lymph node count (LNC), lymph node ratio (LNR), and surgical extent \[[@CR6]\]. All of these elements are inseparable qualities of a "successful cancer career," of which more detailed evaluations are still required, however.

We anticipate that the combined performance of the above-mentioned factors is superior to that of the AJCC stages and may serve as a more precise and reproducible tool for individualized survival estimations. We have herein incorporated clinically important variables with data from the Surveillance, Epidemiology, and End Results (SEER) database to develop validated prognostic nomograms for predicting CSS and OS of patients with surgically treated CRC without neoadjuvant therapies.

Methods {#Sec2}
=======

Patient eligibility and variables {#Sec3}
---------------------------------

The SEER program is a national database and primary source of cancer statistics that is currently maintained by the National Cancer Institute \[[@CR22]\]. The data of patients with CRC diagnosed from 2004 to 2010 were retrieved from the SEER research database using the SEER\*Stat program (v 8.2.1) \[[@CR22]\]. In total, 265,030 records were retrieved. Any surgically treated, pathologically proven, staged colorectal adenocarcinomas were considered. Only patients who met the following criteria were included in the formal analysis: (1) known preoperative CEA status, (2) no history of malignancy, (3) microscopically proven stage I to IV primary adenocarcinoma (including signet ring cell carcinoma), (3) no adjuvant therapy before surgery, (4) cancer-directed surgery of primary tumors with sufficient information to specify the T/N/M stage and LNC/LNR, (5) active follow-up with complete date and known outcome, and (6) adequate/consistent information to specify the primary tumor site, size, and other variables. Patients aged \<18 or \>99 years and those with multiple primary cancers were excluded. Patients were also excluded if their T/N did not meet pathological staging criteria (not pT/N). These patients were small in number, but they might have introduced bias to the survival analysis; thus, they were excluded.

The following variables were assessed: sex, age, race, marital status, year of diagnosis, primary tumor location, size, histology, grade, TNM stage, LNC, cause-specific death, and vital status. Cancer stages reported using the 6th AJCC/TNM stages (AJCC6) were converted based on the 7th edition (AJCC7). The LNR was calculated by dividing metastatic node number by the LNC.

After patient exclusion based on the above-mentioned criteria, 56,072 eligible patients were identified. Patients diagnosed from 2004 to 2007 were randomized into a training cohort and a contemporary validation cohort (ratio, 90:10). The remaining patients were diagnosed from 2008 to 2010 and were thus assigned to a prospective test cohort (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Flow diagram of patient selection and study development

Statistical methods {#Sec4}
-------------------

Discontinuous variables were categorized before modeling based on clinical reasoning and significance. Linear assumptions of continuous variables (age, LNC, and LNR) were relaxed with restricted cubic spline functions to determine the optimal number of knots by maximizing goodness of fit using the log-likelihood and minimizing information loss using the Akaike information criterion (AIC) \[[@CR23]\]. Multivariate models for nomograms were built by incorporating significant variables from univariate Cox proportional hazard regressions in a backward stepwise manner based on the AIC. Model performance was appraised using the concordance index (c-index) and internally testified by 200-sample bootstrap validation and calibration. External validation was performed by applying nomograms to the contemporary validation cohort and prospective test cohort separately, followed by evaluation of similar statistics in the new data sets. Different c-indexes were compared using the *compareC* \[[@CR24]\] package. Next, patients in all cohorts were given an aggregated score using standard points derived from the nomograms. Time-dependent receiver-operating characteristic (ROC) curve analysis was performed with the *timeROC* \[[@CR25]\] package to evaluate the performance of the nomograms with the accumulated scores as a continuous predictive variable. The nomograms were compared with the AJCC6/7 stages by risk classification and stratification using Kaplan--Meier survival curves and statistically clarified by quantifying the cumulative 5-year survival and hazard ratios for each stratum. Briefly, risk classification was achieved by ranking the accumulated nomogram scores by deciles to derive 10 risk groups (Nomo stages) with patients in the training cohort. For risk stratification, the patients were divided by score tertiles for each AJCC7 substage to generate three prognostic strata: low-, median-, and high-risk. The two external cohorts were likewise classified and stratified according to thresholds defined by the training cohort. Next, mosaic plots were drawn to demonstrate the AJCC7 stage distributions in contrast with the Nomo stages. After addressing the accuracy of the nomograms, decision curve analysis (DCA) \[[@CR26]\] was performed to finalize the ranges of threshold probabilities within which the nomograms were clinically valuable. The patients were randomly allocated using the PASW 18.0 program (SPSS Inc., Chicago, IL); the other analyses were processed with the R program (v 3.2.3) using *rms* \[[@CR23]\] and the above-mentioned packages. Only a two-tailed *P* value of \<0.05 was considered statistically significant. This study followed the TRIPOD statement \[[@CR27]\] and adhered to the Declaration of Helsinki for medical research involving human subjects \[[@CR28]\].

Results {#Sec5}
=======

Baseline characteristics {#Sec6}
------------------------

The characteristics of the patients in the derivation and validation cohorts are shown in Table [1](#Tab1){ref-type="table"}.Table 1Characteristics of patients with colorectal cancerVariablesTraining cohortValidation cohortTest cohort(*n* = 27700)(*n* = 3158)(*n* = 25214)Sex, n, % Female1407750.8160550.81270250.4 Male1362349.2155349.21251249.6Age, year, median, range6718--996718--996718--99Race, n, % White2172278.4242876.91971078.2 Black342212.441213.0310612.3 Yellow (Chinese, Korean and Japanese)12294.41695.410754.3 Other13274.81494.713235.2Marital status at diagnosis, n, % Married (including separated)1590057.4181257.31416656.2 Divorced23788.62668.422979.1 Single (never married)351912.740612.9355314.1 Widowed518518.760119.1436317.3 Unknown7182.6732.38353.3CEA status, n, % Negative1555056.1180357.11482458.8 Positive1215043.9135542.91039041.2Tumor site, n, % Proximal colon (cecum to splenic flexure)1434151.7162151.31379054.7 Distal colon (descending to sigmoid colon)801529.095230.2744129.5 Overlapping lesion of colon2841.0240.82751.1 Rectum (including rectosigmoid junction)506018.356117.7370814.7Tumor size, n, % ≤ 5 cm1686160.9196662.31517860.2 \> 5 cm912032.999831.6855733.9 Unknown17196.21946.114795.9Extent of surgery, n, % Local/segmental resection1287946.5150547.71146445.5 Subtotal/hemisection1399150.5154949.01313752.1 Total resection8303.01043.36132.4Histology, n, % Adenocarcinoma2737598.8311698.72497599.1 Signet ring cell carcinoma3251.2421.32390.9Tumor grade, n, % Well to Moderately differentiated (G1 + G2)2113776.3243577.11945077.2 Poorly to Undifferentiated (G3 + G4)593121.464620.5520220.6 Unknown6322.3772.45622.2pT stage, n, % pT123818.62728.6266210.6 pT2398714.444714.2384415.2 pT31709461.7198062.71488759.0 pT4a22448.12568.122428.9 pT4b19947.22036.415796.3pN stage, n, % N01406950.8161551.11337853.1 N1a344512.440212.7300511.9 N1b396014.345614.4337813.4 N2a305511.035611.2261110.4 N2b317111.532910.4284211.2Lymph node count, mean, sd15.79.615.89.618.49.6Lymph node ratio, mean, IQR0.160--0.240.160--0.220.130--0.18Metastasis, n, % M02251281.3258781.92111283.7 M1518818.757118.1410216.3 Follow-up631--107641--107341--59Number of events93411335910551496565976891-year cumulative survival87.984.188.684.789.886.53-year cumulative survival73.867.175.168.777.370.95-year cumulative survival ^a^66.657.267.758.670.860.6^a^Survival probabilities of the test cohort at 5 years were approximated at 59 months*CEA* carcinoembryonic antigen, *sd* standard deviation, *IQR* interquartile range, *CSS* cancer-specific survival, *OS* overall survival

Cox regression of training cohort {#Sec7}
---------------------------------

No continuous variables (age, LNC, or LNR) had linear effects on either CSS or OS (Fig. [2](#Fig2){ref-type="fig"}). All variables assessed in the univariate analysis (Table [2](#Tab2){ref-type="table"}) remained significant in the multivariate Cox regressions except tumor size (Table [3](#Tab3){ref-type="table"}).Fig. 2Adjusted relative hazards with continuous variables. **a**--**c** The optimized number of knots applied in the multivariate analysis of CSS was 4, 6, and 3 for age, LNC, and LNR, respectively. **d**--**f** These numbers of knots were 4, 6, and 4 for the same three variables in the analysis of OS. RCS, restricted cubic spline function; CSS, cancer-specific survival; OS, overall survival; LNC, lymph node count; LNR, lymph node ratioTable 2Univariate cox regression analysis of training cohortVariablesCancer-specific survivalOverall survivalHR95 % CI*P*HR95 % CI*P*Sex Femalerefref Male1.0601.018--1.1040.00491.0551.019--1.0910.0021Race Whiterefref Black1.2781.206--1.354\<0.00011.1571.101--1.216\<0.0001 Yellow (Chinese, Korean and Japanese)0.7620.682--0.850\<0.00010.7010.638--0.770\<0.0001 Other0.9740.884--1.0720.58500.8700.800--0.9460.0011Marital status at diagnosis Married (including separated)refref Divorced1.1711.088--1.259\<0.00011.1751.103--1.251\<0.0001 Single (never married)1.3321.255--1.414\<0.00011.3161.250--1.386\<0.0001 Widowed1.3761.305--1.450\<0.00011.7461.675--1.821\<0.0001 Unknown1.0450.914--1.1960.51751.2461.120--1.3870.0001CEA status Negativerefref Positive3.1743.042--3.313\<0.00012.4492.366--2.535\<0.0001Tumor site Proximal colonrefref Distal colon0.8920.850--0.935\<0.00010.8350.803--0.869\<0.0001 Overlapping lesion of colon1.3821.153--1.6570.00051.2941.108--1.5100.0011 Rectum0.8800.833--0.931\<0.00010.8250.787--0.865\<0.0001Tumor size ≤ 5 cmrefref \> 5 cm1.4291.370--1.491\<0.00011.3161.270--1.363\<0.0001 Unknown0.8210.746--0.9040.00010.8060.745--0.873\<0.0001Extent of surgery Local/segmental resectionrefref Subtotal/hemisection1.1611.114--1.211\<0.00011.1811.141--1.223\<0.0001 Total resection1.5271.373--1.699\<0.00011.3881.264--1.525\<0.0001Histology Adenocarcinomarefref Signet ring cell carcinoma2.6482.304--3.044\<0.00012.1801.916--2.480\<0.0001Tumor grade G1/G2refref G3/G41.9031.820--1.989\<0.00011.6141.553--1.678\<0.0001 Unknown1.0070.871--1.1640.92830.9420.834--1.0640.3372pT stage pT1refref pT21.8541.556--2.209\<0.00011.6621.495--1.848\<0.0001 pT36.1615.285--7.182\<0.00013.1502.871--1.848\<0.0001 pT4a13.42211.43--15.760\<0.00015.7755.21--6.400\<0.0001 pT4b17.42914.844--20.464\<0.00017.3246.607--8.120\<0.0001Metastasis M0refref M17.7337.414--8.066\<0.00014.9534.773--5.139\<0.0001*HR* hazard ratio, *95 % CI* 95 % confident interval, *ref* reference category, *CEA* carcinoembryonic antigenTable 3Multivariate cox regression analysis of training cohortCancer-specific survivalOverall survivalCovariatesHR95 % CI*P*HR95 % CI*P*Sex (Male vs. Female)1.1421.094--1.193\<0.00011.2461.202--1.293\<0.0001Race (ref, White) Black1.1991.130--1.273\<0.00011.1911.132--1.254\<0.0001 Yellow (Chinese, Korean, Japanese)0.7840.702--0.875\<0.00010.7130.649--0.784\<0.0001 Other1.0300.935--1.1350.54490.9960.915--1.0830.9203Marital status at diagnosis (ref, Married) Divorced1.1751.092--1.265\<0.00011.2141.139--1.293\<0.0001 Single (never married)1.2351.161--1.313\<0.00011.2771.211--1.346\<0.0001 Widowed1.1891.118--1.264\<0.00011.2241.165--1.285\<0.0001 Unknown1.0140.886--1.1610.84241.1451.029--1.2750.0131CEA status (Positive vs. negative)1.5891.517--1.664\<0.00011.4861.431--1.543\<0.0001Extent of surgery (ref, Loc/seg resection) Subtotal/hemisection1.0671.012--1.1250.01561.0400.995--1.0870.0824 Total resection1.2691.139--1.414\<0.00011.1801.073--1.2970.0007Tumor site (ref, Proximal colon) Distal colon0.9100.860--0.962\<0.00010.9180.876--0.9620.0004 Overlapping lesion of colon1.0900.909--1.3070.35451.1110.952--1.2980.1824 Rectum1.0020.935--1.0740.95160.9810.926--1.0400.5211Tumor size (ref, ≤ 5 cm) \>5 cm1.0290.984--1.0760.20501.0260.989--1.0660.1741 Unknown1.1411.035--1.2580.00781.0750.991--1.1660.0810Histology (ref, Adenocarcinoma) Signet ring cell carcinoma1.4091.220--1.626\<0.00011.3801.209--1.575\<0.0001Tumor grade (ref, G1/G2) G3/G41.2781.219--1.339\<0.00011.1841.137--1.233\<0.0001 Unknown1.1430.987--1.3230.07361.0490.927--1.1860.4501pT stage (ref, pT1) pT21.5671.312--1.872\<0.00011.3981.254--1.558\<0.0001 pT32.9492.516--3.457\<0.00011.7961.628--1.981\<0.0001 pT4a4.4293.746--5.237\<0.00012.5082.247--2.799\<0.0001 pT4b4.7604.021--5.634\<0.00012.7462.456--3.069\<0.0001Metastasis (M1 vs. M0)4.0753.876--4.284\<0.00013.3573.213--3.508\<0.0001*HR* hazard ratio, *95 % CI* 95 % confident interval, *ref* reference category, *Loc/seg resection* Local/segmental resection, *CEA* carcinoembryonic antigen

Nomograms for CSS and OS {#Sec8}
------------------------

As selected by the AIC, all tested covariates were employed in the nomograms. The c-indexes were 0.816 (95 % CI 0.810--0.822) and 0.777 (95 % CI 0.772--0.782) for the CSS (Fig. [3a](#Fig3){ref-type="fig"}) and OS (Fig. [3b](#Fig3){ref-type="fig"}) predictive nomograms, respectively. Details of the nomograms' labels and points were shown in Table [4](#Tab4){ref-type="table"} and Table [5](#Tab5){ref-type="table"}.Fig. 3Nomograms for (**a**) CSS and (**b**) OS. Generally, each individual involved covariate was assessed for the patient and given a point on the basis of the nomograms. Aggregated points were obtained by summing the given points of all involved variables. The aggregated points corresponded to particular survival probabilities and median survival years that could be indicated by the nomograms. A higher total number of points frequently indicated a higher possibility of adverse outcomes (CSS or OS) and therefore a lower expected survival. CSS, cancer-specific survival; OS, overall survivalTable 4Points for categorical variables in nomogramsPointsVariablesLabels for tick marksCSSOSSex FemaleFemale00 MaleMale7.59.2Race WhiteWhite13.814.1 BlackBlack24.121.4 Yellow (Chinese, Korean and Japanese)Yellow00 OtherOther15.513.9Marital status at diagnosis Married (including separated)Mar00 DivorcedDiv9.28.1 Single (never married)Sin11.910.2 WidowedWid9.88.4 UnknownUk0.85.7CEA status NegativeNegative00 PositivePositive26.216.6Tumor site Proximal colon (cecum to splenic flexure)Pc5.43.6 Distal colon (descending to sigmoid colon)Dc00 Overlapping lesion of colonOc10.38.0 Rectum (including rectosigmoid junction)Rect5.52.8Tumor size ≤5 cm0--500 \>5 cm5+1.61.1 UnknownUk7.53.0Extent of surgery Local/segmental resectionLoc/Seg00 Subtotal/hemisectionPartial3.71.6 Total resectionTotal13.56.9Histology AdenocarcinomaAdeno00 Signet ring cell carcinomaSignet19.413.5Tumor grade Well to Moderately differentiated (G1 + G2)G1/200 Poorly to Undifferentiated (G3 + G4)G3/413.97.1 UnknownUk7.62.0pT stage pT1T100 pT2T225.514.0 pT3T361.324.5 pT4aT4a84.338.4 pT4bT4b88.442.2Metastasis M0M000 M1M179.650.6*CSS* cancer-specific survival, *OS* overall survival, *CEA* carcinoembryonic antigenTable 5Points for continuous variables in nomogramsAge at diagnosisLymph node count, nLymph node ratioValues, no.Pts for CSSPts for OSValues, no.Pts for CSSPts for OSValues, %Pts for CSSPts for OS100.00.0012.315.700.00.0201.20.11010.29.71015.912.3302.50.2203.43.52030.518.2403.70.3300.00.03042.321.8505.30.8402.91.14050.925.36010.55.9505.92.25057.028.87023.921.1608.93.36061.232.28046.044.87011.94.47064.235.69072.872.28014.95.58066.539.0100100.0100.09017.96.69068.942.410071.245.7*Pts* points, *CSS* cancer-specific survival, *OS* overall survival

Internal validation {#Sec9}
-------------------

The bootstrap-corrected c-indexes (CSS, 0.8157; OS, 0.7768) were close to those of the nomograms. Both models exhibited good validation.

Nomogram calibration {#Sec10}
--------------------

As shown in the calibration plots, the nomogram-predicted 3- and 5-year CSS and OS were well correlated with the corresponding Kaplan--Meier estimates (Fig. [4](#Fig4){ref-type="fig"}), suggesting appreciable reliability of the nomograms.Fig. 4Bootstrap calibrations of nomograms. The predicted 3- and 5-year (**a**, **b**) CSS and (**c**, **d**) OS were well correlated with the actual survival probabilities

External validation {#Sec11}
-------------------

The c-indexes of the nomograms for prediction of CSS and OS were 0.809 (95 % CI 0.791--0.827) and 0.773 (95 % CI 0.757--0.789) in the validation cohort, while the optimism-corrected c-indexes were 0.804 and 0.768, respectively. In the test cohort, the c-indexes were 0.839 (95 % CI 0.830--0.846) and 0.802 (95 % CI 0.796--0.808) with corrected estimates of 0.838 and 0.801 for CSS and OS prediction, respectively. The external calibration plots also showed good validation (Fig. [5](#Fig5){ref-type="fig"}).Fig. 5Bootstrap calibration of nomograms in the external cohorts. The nomograms were externally calibrated in the validation cohort by predicting the 3- and 5-year (**a**, **b**) CSS and (**c**, **d**) OS. The nomograms were also calibrated in the test cohort for the 3-year (**e**) CSS and (**f**) OS. All results showed good validation. CSS, cancer-specific survival; OS, overall survival

Time-dependent ROC curve analysis {#Sec12}
---------------------------------

The areas under the ROC curve (AUCs) for predicting CSS ranged from 83.0 to 87.8 % in the three cohorts from 1 to 7 years. The AUCs for predicting OS varied from 80.6 to 84.6 % during the same years (Table [6](#Tab6){ref-type="table"}). The nomograms exhibited considerable efficiency to discriminate outcomes.Table 6Time-dependent receiver-operating characteristic curves analysisCancer-specific survivalOverall survivalAUC, %AUC, %Study cohort1 year3 years5 years7 years1 year3 years5 years7 yearsTraining cohort85.287.687.586.682.184.184.283.6Validation cohort83.087.186.785.580.683.783.782.7Test cohort86.087.8//83.184.6//*AUC* area under the time-dependent receiver-operating characteristic curves

Comparison of nomograms with AJCC stages {#Sec13}
----------------------------------------

First, when compared with the AJCC6/7 stages, the nomograms yielded the largest log-likelihoods and c-indexes along with the smallest AIC values for CSS and OS prediction in all cohorts (Table [7](#Tab7){ref-type="table"}). These results imply that the nomograms were more robust than the AJCC stages.Table 7Comparison of nomogram with AJCC staging systemNomogram score7^th^ AJCC stage6^th^ AJCC stage*P*Training cohort, CSS AIC172262174703174949/ Log-likelihood−86130−87344−87468All \<0.0001 C-index (95 % CI)0.816 (0.810--0.822)0.777 (0.771--0.783)0.774 (0.768--0.780)All \<0.0001Training cohort, OS AIC250348255973256182/ Log-likelihood−125173−127979−128085All \<0.0001 C-index (95 % CI)0.777 (0.772--0.782)0.698 (0.693--0.0.703)0.696 (0.691--0.701)All \<0.0001Validation cohort, CSS AIC149831526115272/ Log-likelihood^a^−7490−7623−7630All \<0.0001 C-index^b^ (95 % CI)0.809 (0.791--0.827)0.770 (0.752--0.788)0.768 (0.750--0.786)All \<0.0001Validation cohort, OS AIC216112223522244/ Log-likelihood^c^−10805−11110−11116All \<0.0001 C-index^d^ (95 % CI)0.773 (0.757--0.789)0.699 (0.683--0.715)0.697 (0.681--0.713)All \<0.0001Test cohort, CSS AIC102103104057105039/ Log-likelihood−51050−52021−52519All \<0.0001 C-index (95 % CI)0.838 (0.830--0.846)0.794 (0.786--0.802)0.786 (0.778--0.794)All \<0.0001Test cohort, OS AIC141606145343146456/ Log-likelihood−70802−72664−73227All \<0.0001 C-index (95 % CI)0.802 (0.796--0.808)0.723 (0.717--0.729)0.715 (0.709--0.721)All \<0.0001*AJCC* American joint committee on cancer, *AIC* akaike information criterion, *C-index* concordance index, *95 % CI* 95 % confident interval^a^The *P* value comparing 6^th^ and 7^th^ AJCC stage was 0.0003^b^The *P* value comparing 6^th^ and 7^th^ AJCC stage was 0.5187^c^The *P* value comparing 6^th^ and 7^th^ AJCC stage was 0.0006^d^The *P* value comparing 6^th^ and 7^th^ AJCC stage was 0.3709

Second, as depicted by the Kaplan--Meier curves, the ability of the AJCC7 stages to discriminate CSS and OS was mediocre in both the training (Fig. [6a](#Fig6){ref-type="fig"}) and external cohorts (Fig. [7](#Fig7){ref-type="fig"}). However, the Nomo stages performed consistently much better in all cohorts (Figs. [6a](#Fig6){ref-type="fig"} and [7](#Fig7){ref-type="fig"}). Further analysis in the training (Fig. [6b and c](#Fig6){ref-type="fig"}) and test cohorts (Fig. [8](#Fig8){ref-type="fig"}) showed that the nomograms were also able to stratify each AJCC7 stage into three significant prognostic groups with low, medium, and high risks of CSS and OS, respectively. Additional elaborations on the 5-year cumulative survival (Table [8](#Tab8){ref-type="table"}) and hazard ratios (Table [9](#Tab9){ref-type="table"}) of the Nomo stages as well as the stratified risk groups (Table [10](#Tab10){ref-type="table"}) confirmed robust utility of nomograms in both risk classification and stratification.Fig. 6Kaplan--Meier curve analysis of risk classification and stratification in the training cohort. **a** Risk classification of CSS and OS using the 7th edition of the AJCC stages (AJCC7) and Nomo stages (all log-rank *P* values for trend \<0.0001). **b** Risk stratification of CSS for each AJCC7 substage. **c** Risk stratification of OS for each AJCC7 substage (all log-rank *P* values for trend \<0.0001, all log-rank *P* values for pairwise comparisons \<0.05). CSS, cancer-specific survival; OS, overall survival; AJCC, American Joint Committee on CancerFig. 7Kaplan--Meier curve analysis for risk classification of (**a**) CSS and (**b**) OS in the validation and test cohorts. All log-rank *P* values for trend \<0.0001. CSS, cancer-specific survival; OS, overall survivalFig. 8Kaplan--Meier curve analysis for risk stratification of (**a**) CSS and (**b**) OS within each AJCC substage using the test cohort. All log-rank *P* values for trend \<0.0001. CSS, cancer-specific survival; OS, overall survivalTable 8Cumulative survival for Nomo stages in derivation and external validation cohortsTraining cohortValidation cohortTest cohort(Cumulative survival, 60 months, %)(Cumulative survival, 60 months, %)(Cumulative survival, 59 months, %)Nomo stageCSS95 % CIOS95 % CICSS95 % CIOS95 % CICSS95 % CIOS95 % CINomo 196.896.1--97.494.693.7--95.497.796.1--99.495.593.2--97.894.388.7--99.890.885.5--96.1Nomo 294.093.1--95.088.186.9--89.392.990.0--95.887.183.4--90.994.091.5--96.689.086.5--91.4Nomo 390.989.8--92.083.782.4--85.191.288.0--94.486.682.8--90.392.190.5--93.685.583.4--87.7Nomo 487.185.8--88.476.174.5--77.788.184.4--91.778.974.4--83.487.484.5--90.376.573.5--79.5Nomo 582.080.4--83.570.368.6--72.082.377.9--86.767.862.6--73.083.781.8--85.769.162.1--76.1Nomo 674.272.4--75.959.057.2--60.973.668.5--78.759.454.0--64.876.173.9--78.460.156.9--63.3Nomo 763.361.4--65.244.842.9--46.761.355.6--67.050.645.1--56.164.460.3--68.647.443.3--51.5Nomo 843.641.6--45.632.630.9--34.450.844.8--56.832.727.5--37.949.946.9--53.031.827.9--35.7Nomo 922.120.4--23.718.016.5--19.423.918.8--29.020.215.8--24.720.216.0--24.417.815.0--20.6Nomo 105.74.7--6.64.84.0--5.68.45.2--11.67.34.5--10.26.33.9--8.63.81.3--6.3*P* ~log-rank~ for trend\<0.0001\<0.0001\<0.0001\<0.0001\<0.0001\<0.0001*CSS* cancer-specific survival, *OS* overall survival, *Nomo* Nomo stagesTable 9Relative hazard for Nomo stages in derivation and external validation cohortsTraining cohortValidation cohortTest cohortNomo stagesCut-off PointsHR95 % CI*P*HR95 % CI*P*HR95 % CI*P*Cancer-specific survival Nomo 1≤82.0refrefref Nomo 2≤106.21.861.48--2.35\<0.00012.401.19--4.840.01471.921.37--2.700.0002 Nomo 3≤122.92.862.30--3.55\<0.00013.331.70--6.510.00043.382.48--4.62\<0.0001 Nomo 4≤138.23.913.17--4.82\<0.00014.832.54--9.22\<0.00015.133.81--6.91\<0.0001 Nomo 5≤153.05.584.55--6.84\<0.00016.603.50--12.42\<0.00017.875.89--10.51\<0.0001 Nomo 6≤170.78.476.95--10.33\<0.000110.415.60--19.32\<0.000112.179.19--16.13\<0.0001 Nomo 7≤192.212.4610.25--15.14\<0.000116.238.84--29.81\<0.000118.3913.91--24.3\<0.0001 Nomo 8≤225.622.4018.49--27.13\<0.000121.1111.53--38.67\<0.000132.1924.47--42.34\<0.0001 Nomo 9≤272.140.4733.46--48.94\<0.000142.8723.56--78.00\<0.000165.3249.79--85.68\<0.0001 Nomo 10272.1+83.3168.9--100.73\<0.000186.0747.39--156.31\<0.0001127.4697.2--167.12\<0.0001Overall survival Nomo 1≤57.2refrefref Nomo 2≤70.02.161.83--2.56\<0.00011.961.19--3.220.00782.131.68--2.70\<0.0001 Nomo 3≤80.83.042.59--3.58\<0.00012.631.64--4.210.00013.122.49--3.92\<0.0001 Nomo 4≤90.74.764.08--5.56\<0.00014.282.73--6.71\<0.00015.554.48--6.87\<0.0001 Nomo 5≤101.66.125.26--7.12\<0.00016.173.99--9.55\<0.00016.905.59--8.52\<0.0001 Nomo 6≤114.29.017.76--10.45\<0.00018.415.47--12.92\<0.000111.119.06--13.63\<0.0001 Nomo 7≤129.113.4611.62--15.58\<0.000111.257.36--17.19\<0.000115.2312.45--18.62\<0.0001 Nomo 8≤147.118.6816.15--21.61\<0.000116.8111.04--25.61\<0.000124.2319.85--29.57\<0.0001 Nomo 9≤171.828.4424.61--32.88\<0.000125.4716.76--38.68\<0.000137.6630.91--45.89\<0.0001 Nomo 10171.8+55.2547.8--63.86\<0.000145.2729.80--68.76\<0.000175.0761.63--91.45\<0.0001*HR* hazard ratio, *95 % CI* 95 % confident intervalTable 10Risk stratifications for each AJCC substage in training and test cohortsTraining cohortTest cohortAJCC stagesCut-off PointsCumulative Survival, 60 months, %HR95 % CIPairwise *P* ~log-rank~HR95 % CIPairwise *P* ~log-rank~Cancer-specific survival Stage I  Low risk group (L)≤70.097.7refL v M \< 0.0001refL v M \< 0.0205  Median risk group (M)≤97.294.42.441.91--3.13L v H \< 0.00011.751.24--2.45L v H \< 0.0001  High risk group (H)97.2+88.44.733.66--6.12M v H \< 0.00016.124.27--8.77M v H \< 0.0001 Stage IIA  Low risk group (L)≤122.793.9refL v M \< 0.0001refL v M \< 0.0001  Median risk group (M)≤149.487.71.901.64--2.19L v H \< 0.00012.111.4--2.58L v H \< 0.0001  High risk group (H)149.4+76.23.963.41--4.61M v H \< 0.00014.663.80--5.72M v H \< 0.0001 Stage IIB  Low risk group (L)≤151.284.4refL v M = 0.0046refL v M = 0.0220  Median risk group (M)≤178.471.11.841.28--2.64L v H \< 0.00012.091.29--3.39L v H \< 0.0001  High risk group (H)178.4+54.13.302.22--4.90M v H \< 0.00125.273.16--8.81M v H \< 0.0001 Stage IIC  Low risk group (L)≤158.076.7refL v M = 0.0121refL v M = 0.6571  Median risk group (M)≤181.862.31.641.16--2.31L v H \< 0.00011.120.72--1.74L v H \< 0.0001  High risk group (H)181.8+45.62.791.93--2.03M v H \< 0.00202.731.68--4.42M v H \< 0.0001 Stage IIIA  Low risk group (L)≤88.994.8refL v M = 0.0116refL v M \< 0.0210  Median risk group (M)≤120.291.62.041.39--2.99L v H \< 0.00012.511.36--4.63L v H \< 0.0001  High risk group (H)120.2+75.66.844.57--10.24M v H \< 0.00016.543.20--13.35M v H = 0.0015 Stage IIIB  Low risk group (L)≤147.685.9refL v M \< 0.0001refL v M \< 0.0001  Median risk group (M)≤180.372.12.091.89--2.32L v H \< 0.00012.352.04--2.70L v H \< 0.0001  High risk group (H)180.3+50.14.253.80--4.76M v H \< 0.00015.344.55--2.67M v H \< 0.0001 Stage IIIC  Low risk group (L)≤187.265.1refL v M \< 0.0001refL v M \< 0.0001  Median risk group (M)≤218.041.61.991.74--2.27L v H \< 0.00012.011.72--2.36L v H \< 0.0001  High risk group (H)218.0+24.83.493.01--4.04M v H \< 0.00014.053.39--4.84M v H \< 0.0001 Stage IV  Low risk group (L)≤255.626.2refL v M \< 0.0001refL v M \< 0.0001  Median risk group (M)≤292.112.01.561.46--1.67L v H \< 0.00011.851.70--2.01L v H \< 0.0001  High risk group (H)292.1+4.02.782.57--3.01M v H \< 0.00013.343.20--3.70M v H \< 0.0001Overall survival Stage I  Low risk group (L)≤55.194.6refL v M \< 0.0001refL v M \< 0.0001  Median risk group (M)≤79.984.52.942.58--3.35L v H \< 0.00013.102.58--3.72L v H \< 0.0001  High risk group (H)79.9+63.19.077.90--10.41M v H \< 0.000110.708.80--13.01M v H \< 0.0001 Stage IIA  Low risk group (L)≤75.990.6refL v M \< 0.0001refL v M \< 0.0001  Median risk group (M)≤101.477.02.662.42--2.91L v H \< 0.00012.862.50--3.28L v H \< 0.0001  High risk group (H)101.4+49.17.386.68--8.15M v H \< 0.00017.806.77--8.97M v H \< 0.0001 Stage IIB  Low risk group (L)≤93.580.3refL v M = 0.0007refL v M \< 0.0001  Median risk group (M)≤120.464.71.861.40--2.45L v H \< 0.00013.862.60--5.72L v H \< 0.0001  High risk group (H)120.4+26.85.484.00--7.49M v H \< 0.00018.035.27--12.22M v H \< 0.0001 Stage IIC  Low risk group (L)≤96.973.6refL v M \< 0.0001refL v M = 0.2111  Median risk group (M)≤121.954.42.091.56--2.80L v H \< 0.00011.350.92--1.98L v H \< 0.0001  High risk group (H)121.9+35.53.542.58--4.86M v H = 0.00023.812.46--5.91M v H \< 0.0001 Stage IIIA  Low risk group (L)≤60.094.6refL v M \< 0.0001refL v M \< 0.0316  Median risk group (M)≤90.484.33.672.76--4.87L v H \< 0.00012.101.36--3.25L v H \< 0.0001  High risk group (H)90.4+59.411.718.66--15.84M v H \< 0.00019.075.70--14.45M v H \< 0.0001 Stage IIIB  Low risk group (L)≤91.082.3refL v M \< 0.0001refL v M \< 0.0001  Median risk group (M)≤116.963.72.282.09--2.48L v H \< 0.00012.722.42--3.07L v H \< 0.0001  High risk group (H)116.9+36.65.064.60--5.56M v H \< 0.00016.555.75--7.47M v H \< 0.0001 Stage IIIC  Low risk group (L)≤110.663.3refL v M \< 0.0001refL v M \< 0.0001  Median risk group (M)≤137.035.72.101.86--2.37L v H \< 0.00011.941.68--2.24L v H \< 0.0001  High risk group (H)137.0+18.23.973.47--4.55M v H \< 0.00014.333.68--5.11M v H \< 0.0001 Stage IV  Low risk group (L)≤157.224.2refL v M \< 0.0001refL v M \< 0.0001  Median risk group (M)≤183.39.91.591.49--1.69L v H \< 0.00011.871.73--2.03L v H \< 0.0001  High risk group (H)183.3+3.02.792.58--3.01M v H \< 0.00013.513.19--3.88M v H \< 0.0001*AJCC* American joint committee on cancer, *HR* hazard ratio, *95 % CI* 95 % confident interval, *L* low risk group, *M* median risk group, *H* high risk group

Finally, the mosaic plots demonstrated significant survival heterogeneity within individual AJCC7 substages in contrast to the Nomo stages (Fig. [9](#Fig9){ref-type="fig"}). The results offer direct evidence and the underlying frequencies of staging errors in the conventional AJCC staging system.Fig. 9Mosaic plots using the training cohort. **a** CSS, **b** OS. In the mosaic plots, each of the 10 deciles is represented by 1 of 10 consecutive rainbow colors. The area of the individual mosaics represents the relative frequency associated with the column cell. The short segmented lines indicate a frequency of zero. CSS, cancer-specific survival; OS, overall survival; AJCC, American Joint Committee on Cancer

Decision curve analysis {#Sec14}
-----------------------

After addressing the model accuracy, DCA was applied to render clinical validity to the nomograms in the derivation cohort and generalize it to the external cohorts. The results corroborated good clinical applicability of the nomograms in predicting survival of patients with CRC because their ranges of threshold probabilities were wide and practical in all cohorts (Fig. [10](#Fig10){ref-type="fig"}). Additional comparisons of model competence were also in favor of the nomograms' superiority over the conventional AJCC stages because the net benefit for the patients was consistently enhanced (higher lines for model prediction relative to the horizontal lines) when using the nomograms compared with using the TNM stages (Fig. [10](#Fig10){ref-type="fig"}).Fig. 10Decision curve analysis of nomograms in different cohorts and model comparisons with AJCC stages. **a** One-, 3-, and 5-year CSS in the training cohort. **b** One-, 3-, and 5-year OS in the training cohort. **c** One-, 3-, and 5-year CSS in the validation cohort. **d** One-, 3-, and 5-year OS in the validation cohort. **e** One- and 3-year CSS in the test cohort. **f** One- and 3-year OS in the test cohort. **g** Nomogram comparisons of the 6th and 7th versions of the AJCC stages for predicting 5-year CSS in the training cohort. **h** Nomogram comparisons of the 6th and 7th versions of the AJCC stages for predicting 5-year OS in the training cohort. Cyan horizontal lines represent the assumption that events occurred in no patient within a particular timespan. Red lines represent the assumption that events occurred in all patients within the same timespan. Blue lines represent the net benefit of model prediction. The net benefit per patient of each predictive model within a particular timespan was a function of the cohort size with threshold probability, and was computed by addition of the benefit (true positive) and subtraction of the harm (false positive). **g**, **h** Note that the red "assume all" lines overlap and appear to be a single line for both the nomogram and the 6th- and 7th-version AJCC stages prediction. This occurred because they were constructed using the same cohorts and time points. CSS, cancer-specific survival; OS, overall survival; AJCC, American Joint Committee on Cancer

Discussion {#Sec15}
==========

In the present study, we developed two postoperative nomograms to predict CSS and OS for patients who have undergone CRC resection without neoadjuvant therapy. The nomograms consistently achieved considerable predictive accuracy and appreciable reliability and reproducibility when applied to the derivation and validation cohorts. DCA subsequently demonstrated significant clinical applicability of the nomograms with wide threshold probabilities. In addition, model comparisons and DCA proved that the nomograms outperformed the conventional AJCC stages by stratifying them into three significant prognostic groups and allowing for more robust risk classification (Nomo stages) with an improved net benefit.

Prognostic nomograms are simplified representations of complicated statistical models with elegant graphics \[[@CR18], [@CR29], [@CR30]\]. Compared with other predictive models, they are more accurate and comprehensible with user-friendly interfaces, allowing for wide application in clinical practice \[[@CR18], [@CR29], [@CR30]\]. A recent systematic review summarized the basic characteristics of more than 16 predictive nomograms for CRC \[[@CR31]\]. Although patient definitions, endpoints, and time points are markedly heterogeneous, most of the nomograms have demonstrated improved accuracy. Our study shows some distinctions from those published nomograms, however.

First, no previous studies incorporated both patients with non-metastatic CRC and those with metastatic CRC. Because both non-metastatic and metastatic CRC are continuous representations of systemic tumor biology, exclusion of patients with metastasis may inherit the limitations of the AJCC stages. Second, we used population-based data to derive nomograms for CRC; this may be considered an update and extension of a previously published nomogram that also used SEER data but concentrated on curative stage I to III colonic adenocarcinomas \[[@CR32]\]. Population-based data often fail to include detailed data and novel markers such as the CEA concentration \[[@CR19]\] and microRNAs \[[@CR33]\], which may be helpful to increase model accuracy. However, population-based data are more likely to overcome inconsistency biased by institutional practice \[[@CR18]\]. Third, we selected covariates based on the AIC instead of statistical significance (*P* value), allowing for confidence in the robustness of modeling and performance \[[@CR34]\]. The *P* values depend not only on the magnitude of the predictors' effects but also on the sample size. Small data sets are less likely to discriminate small differences, and their use makes it more difficult to reject the null hypothesis. We also used restricted cubic spline functions for continuous variables to avoid unnecessary information loss caused by categorization \[[@CR23]\]. Finally, we introduced DCA and proved the clinical validity of our nomograms. High predictive accuracy is not necessarily associated with usefulness in clinical practice. Well-performing models may have limited applicability if the threshold probabilities of the net benefits are impractical, meaning that the new predictive models will be less beneficial than currently available tools and may even be harmful \[[@CR18], [@CR26]\].

Our study also produced some novel findings besides the many results consistent with previous studies. Above all, based on the nomograms, we have proposed Nomo stages and efficiently classified stage I to IV CRCs into 10 significant subgroups with a single predictive score. Our nomograms also enable stratification of each AJCC7 substage into three significant risk strata, which has not been achieved by other CRC nomograms. This risk classification and stratification may be very useful for clinicians to identify postoperative patients with high risks associated with intensified follow-up (i.e., patients with high-risk stage I CRC) and select less heterogeneous patients for clinical trials (i.e., patients with high-risk stage II CRC). This also helps to understand the degree of survival heterogeneity in the AJCC stages, which frequently introduces confusion and uncertainty to patient consulting. Note that the optimal thresholds for risk classification and stratification may be individualized, although the thresholds defined by the training cohort still worked well in our external cohorts, which are only intended for relatively strict validation. Additionally and importantly, the sharing of similar contributing predictors is a reflection of apparent correlations between CSS and OS. Some of these predictors are worth noting here. In our models, age had a persistent effect but multiplied from beyond 60 years old. Age is a traditional reference for physical condition, frequency and efficiency of reinforced therapies, thus exerts an accumulated effect on survival. It is reasonable to presume that certain tumor-related factors such as infiltration depth, metastasis, histology, LNR, and LNC are relatively more important predictors than age. They are typical features of tumor development and are closely related to patient death at various but statistically significant levels. The LNC is one of the most controversial among these tumor-related factors. It has been proposed as a quality indicator \[[@CR6], [@CR35]\] and is augmented in extended lymphadenectomy, the relevant long-term benefit of which has not been effectively demonstrated because of the absence of prospective clinical trials of extended colonic surgeries \[[@CR35], [@CR36]\]. Inadequate LNC assessment is involved in interpretation of stage migration, which is considered a source of survival heterogeneity in patients with CRC, but its influences are limited \[[@CR14], [@CR35], [@CR36]\]. Several previous studies classified patients by the 12-node benchmark to derive high- and low-risk subpopulations but achieved inconsistent results, while our results indicate that such classification might be associated with a risk of dichotomizing complex, non-linear effects of LNC on patient survival \[[@CR37]\]. Moreover, our analyses indicated that LNC was less superior to LNR, which explains the reduced survival in the patient subset with limited numbers of metastatic nodes. Additionally, the preoperative CEA concentration provides a baseline quantification of the tumor burden and severity of disease. The CEA concentration, with its individualized information and wide application, is due to play a role in the staging of CRC. Next, the effects of racial background may be multifactorial. The lowest prevalence and mortality of CRC are seen in East Asians because of the low prevalence of risk factors such as smoking and obesity in this population \[[@CR1], [@CR2]\]. The highest incidence and mortality are seen in black people \[[@CR2]\]; this can be ascribed to the lower income, later diagnosis, and less access to high-quality health care in this population \[[@CR2], [@CR20]\]. Additionally, marriage makes a prognostic difference \[[@CR20]\] and deserves more attention because it may provide compensative mechanisms for improvements in survival. Marital status and ethnicity were introduced to prognostic nomograms for CRC for the first time in the present study. It should also be noted that the nomogram points translated from the models' coefficients reflect the importance of the variables relative to the presence of the other covariates. They may vary depending on the outcomes measured. Due to the existence of competing risks, the predictive accuracy for OS tended to be lower than that for CSS in our study. However, we chose a Cox proportional hazard model without competing risks because it was easier to interpret, compare, and comprehend \[[@CR38]\].

Our study has limitations that deserve attention. Improved model accuracy frequently comes at the cost of increased complexity. The tradeoffs between comprehensiveness and comprehensibility are not easy to balance, and this is a common problem during modeling for nomograms. Considering this, we only selected variables that were clinically important and practical with high reproducibility and low time-varying effects. The nomogram itself is associated with uncertainty. Therefore, we provided 95 % CIs for the c-indexes and calibrations to determine the degree of uncertainty. Because of the shorter follow-up, the c-indexes were slightly higher in the test cohort than in the derivation cohort. However, the time-dependent ROC showed that the predictive AUCs of the nomograms in different cohorts were very close in the same years. Moreover, our nomograms were developed for risk assessment and selection of patients who might benefit from additional interventions after surgery. These interventions may include but are not restricted to adjuvant therapies, strengthened treatments, intensified follow-ups, and motivated patient consulting. Even so, nomograms cannot substitute for clinicians' judgments or act as exclusive evidence for clinical decision-making. Finally, details regarding tumor deposit, curability of stage IV CRC, and postoperative chemoradiotherapy among the patients in the present study are unknown, placing a limitation on the survival analysis. Incorporation of the new predictors and introduction of competing risk models may further improve model performance \[[@CR18], [@CR29]\]. However, this will require new nomograms with different modeling strategies.

Conclusions {#Sec16}
===========

In the present study, the bootstrap-corrected and prospectively validated nomograms were consistently reliable and clinically practical with wide threshold probabilities. Moreover, the nomograms outperformed the conventional AJCC stages by allowing for more robust risk classification and stratifying the AJCC stages with an improved net benefit. However, independent external validations are still required in the future.
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